 Aerie Pharmaceuticals, Inc. NASDAQ:AERI, an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported positive topline results for the Companys Phase 2 clinical trial evaluating AR-1105 dexamethasone intravitreal implant in patients with macular edema associated with retinal vein occlusion. 